-
Product Insights
NewNet Present Value Model: BELLUS Health Inc’s BLU-5937
Empower your strategies with our Net Present Value Model: BELLUS Health Inc's BLU-5937 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Blu Solar Melilli 2 Solar PV Park
Blu Solar Melilli 2 Solar PV Park is a solar PV project located in Sicily, Italy. The project is owned and being developed by Blusolar Uno Srl. The project is at the permitting stage. Empower your strategies with our Blu Solar Melilli 2 Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pralsetinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Solid Tumor Drug Details: Pralsetinib (Gavreto) is an anticancer...
-
Case Studies
NewMountain Tourism – Case Study
Mountain Tourism Report Overview The mountain tourism case study offers detailed insights into the key destinations with opportunities and challenges faced by the industry. Mountains are important tourist destinations around the world and attract visitors for their picturesque beauty, sports attractions, and rich cultural and spiritual heritage. The expansion of transportation networks and digitalization has led to an increased interest in mountain tourism both for adventure and wellness. Mountain tourism allows tourists to witness and experience the environment in a...
-
Product Insights
NewNet Present Value Model: Vertex Pharmaceuticals Inc’s VX-548
Empower your strategies with our Net Present Value Model: Vertex Pharmaceuticals Inc's VX-548 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-222 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BLU-222 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BLU-222 in Ovarian Cancer Drug Details: BLU-222 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-222 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BLU-222 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BLU-222 in Gastric Cancer Drug Details: BLU-222 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-451 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BLU-451 in Non-Small Cell Lung Cancer Drug Details: BLU-451 (LNG-451) under development for the treatment...